2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian follow-upMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regression
2022
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidanceEffectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis
Xu D, Dai B, Tan W, Zhao H, Wang W, Kang J. Effectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis. Therapeutic Advances In Respiratory Disease 2022, 16: 17534666221091931. PMID: 35467449, PMCID: PMC9047804, DOI: 10.1177/17534666221091931.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInitiation of high-flow nasal cannulaHigh-flow nasal cannula failureSequential Organ Failure AssessmentRegister of Randomized Controlled TrialsCOVID-19 patientsBody mass indexFailure groupROX indexRisk factorsHigher heart rateWhite blood cellsNasal cannulaChronic Health Evaluation (APACHE) II scoreEfficacy of high-flow nasal cannulaHeart rateDuration of HFNCOdds ratioCochrane Central Register of Randomized Controlled TrialsRisk of HFNC failureHigher white blood cellWhite blood cell countLower ROX indexOrgan Failure AssessmentPooled odds ratio
2019
PE38 Determining adverse risk factors for urinary continence recovery after robotic radical prostatectomy and methods to enable early recovery
Sridhar A, Tan W, Rawlinson A, Pavan N, Gu D, Shaw G, Nathan S, Rajan P, Kelkar A, Allen C, Sooriakumaran P, Briggs T. PE38 Determining adverse risk factors for urinary continence recovery after robotic radical prostatectomy and methods to enable early recovery. European Urology Open Science 2019, 18: e2602. DOI: 10.1016/s1569-9056(19)32724-1.Peer-Reviewed Original Research
2010
[Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome].
Dai B, Kang J, Wang Z, Kong D, Tan W, Zhao H. [Risk factors of novel severe influenza A(H1N1) with concurrent adult respiratory distress syndrome]. National Medical Journal Of China 2010, 90: 2392-5. PMID: 21092507.Peer-Reviewed Original ResearchConceptsAdult respiratory distress syndromeT lymphocyte subsetsSevere influenza AMultivariate logistic regression analysisNon-ARDS groupInfluenza ANon-smoking groupLogistic regression analysisStatistically significant differenceRisk factorsIncidence of adult respiratory distress syndromeAdult respiratory distress syndrome patientsNovel influenza APatient lymphocyte countsRespiratory distress syndromeSignificant differenceControlled clinical trialsLactate dehydrogenaseRegression analysisDistress syndromeLymphocyte countClinical featuresRetrospective analysisClinical trialsH1N1